EA199900861A1 - Усеченные белки, родственные фактору роста эндотелия сосудов - Google Patents
Усеченные белки, родственные фактору роста эндотелия сосудовInfo
- Publication number
- EA199900861A1 EA199900861A1 EA199900861A EA199900861A EA199900861A1 EA 199900861 A1 EA199900861 A1 EA 199900861A1 EA 199900861 A EA199900861 A EA 199900861A EA 199900861 A EA199900861 A EA 199900861A EA 199900861 A1 EA199900861 A1 EA 199900861A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- truncated
- crp
- proteins
- growth factor
- tracked
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84298497A | 1997-04-25 | 1997-04-25 | |
PCT/US1998/007801 WO1998049300A2 (en) | 1997-04-25 | 1998-04-20 | Truncated vegf-related proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
EA199900861A1 true EA199900861A1 (ru) | 2000-06-26 |
Family
ID=25288752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA199900861A EA199900861A1 (ru) | 1997-04-25 | 1998-04-20 | Усеченные белки, родственные фактору роста эндотелия сосудов |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0977854A2 (zh) |
JP (1) | JP2001524828A (zh) |
KR (1) | KR20010020259A (zh) |
CN (2) | CN1260835A (zh) |
AU (1) | AU7250298A (zh) |
CA (1) | CA2287538A1 (zh) |
EA (1) | EA199900861A1 (zh) |
IL (1) | IL132537A0 (zh) |
NZ (2) | NZ514872A (zh) |
WO (1) | WO1998049300A2 (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7153827B1 (en) | 1994-03-08 | 2006-12-26 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 and methods of use |
US6734285B2 (en) | 1994-03-08 | 2004-05-11 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 proteins and compositions |
US7109308B1 (en) | 1994-03-08 | 2006-09-19 | Human Genome Sciences, Inc. | Antibodies to human vascular endothelial growth factor 2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
CN1267550C (zh) | 1994-03-08 | 2006-08-02 | 人体基因组科学有限公司 | 血管内皮生长因子2 |
US5932540A (en) | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7186688B1 (en) | 1994-03-08 | 2007-03-06 | Human Genome Sciences, Inc. | Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2 |
US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
EP0848755B2 (en) | 1995-09-08 | 2011-02-09 | Genentech, Inc. | Vegf-related protein |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
AU3072099A (en) * | 1998-03-13 | 1999-09-27 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DE19813774A1 (de) * | 1998-03-27 | 1999-09-30 | Max Planck Gesellschaft | Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF) |
EP1121143A2 (en) * | 1998-03-27 | 2001-08-08 | Dorothea J. Eicher | Vegf and vegf-c as infant formula supplements |
WO2000014105A1 (en) | 1998-09-08 | 2000-03-16 | Agouron Pharmaceuticals, Inc. | Modifications of the vegf receptor-2 protein and methods of use |
EP1568375A1 (en) * | 1998-10-26 | 2005-08-31 | Ludwig Institute For Cancer Research | Use of VEGF-C or VEGF-D gene or protein to prevent restenosis |
CN1338943A (zh) * | 1998-10-26 | 2002-03-06 | 路德维格癌症研究院 | 利用vegf-c或vegf-d基因或蛋白预防再狭窄 |
US6958147B1 (en) | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
DE69939484D1 (de) | 1998-10-28 | 2008-10-16 | Cornell Res Foundation Inc | Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4 |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
AU4643501A (en) * | 2000-02-04 | 2001-08-14 | Flanders Interuniversity Institute For Biotechnology (Vib) | Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
US7727971B2 (en) | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
AU2001255237B2 (en) * | 2000-04-06 | 2005-12-15 | Wayne P. Franco | Methods of using growth factors for treating heart disease |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
KR20020059609A (ko) | 2000-08-04 | 2002-07-13 | 벤슨 로버트 에이치. | 혈관 내피 성장 인자 2 |
WO2002014367A1 (fr) * | 2000-08-10 | 2002-02-21 | Center For Advanced Science And Technology Incubation,Ltd. | Facteur de croissance chimere de cellules endotheliales vasculaires de type humain |
EP1191104A1 (en) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
CA2431308C (en) | 2000-12-07 | 2010-04-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
DE60236646D1 (de) | 2001-04-13 | 2010-07-22 | Human Genome Sciences Inc | Anti-VEGF-2 Antikörper |
US7402312B2 (en) | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
CA2451311A1 (en) * | 2001-06-20 | 2003-01-03 | Ludwig Institute For Cancer Research | Stimulation of vascularization with vegf-b |
CA2462374C (en) | 2001-10-15 | 2011-01-18 | Janssen Pharmaceutica N.V. | Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
EP1827494A4 (en) * | 2004-11-18 | 2010-02-17 | Wayne Franco | COMBINATION GROWTH THERAPY AND CELL THERAPY FOR THE TREATMENT OF ACUTE AND CHRONIC ORGANIC DISEASES |
US20120141424A1 (en) * | 2009-01-07 | 2012-06-07 | Vegenics Pty Limited | Materials and Methods for the Treatment of Hypertension |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1242149B (it) * | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
WO1994011506A1 (en) * | 1992-11-18 | 1994-05-26 | Arch Development Corporation | Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
EA001616B1 (ru) * | 1995-02-28 | 2001-06-25 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ | Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре |
US5928939A (en) * | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
DE69630442T2 (de) * | 1995-03-02 | 2004-08-19 | Amrad Operations Pty. Ltd., Richmond | Ein neuartiger wachstumsfaktor und eine genetische sequenz, die für diesen codiert |
EP0873348A4 (en) * | 1995-06-06 | 2000-11-08 | Human Genome Sciences Inc | GROWTH FACTOR 3 OF THE HUMAN VASCULAR ENDOTHELIUM |
-
1998
- 1998-04-20 WO PCT/US1998/007801 patent/WO1998049300A2/en not_active Application Discontinuation
- 1998-04-20 JP JP54706298A patent/JP2001524828A/ja not_active Ceased
- 1998-04-20 IL IL13253798A patent/IL132537A0/xx unknown
- 1998-04-20 CN CN98806232A patent/CN1260835A/zh active Pending
- 1998-04-20 AU AU72502/98A patent/AU7250298A/en not_active Abandoned
- 1998-04-20 EP EP98919794A patent/EP0977854A2/en not_active Withdrawn
- 1998-04-20 CN CNA200510009104XA patent/CN1680442A/zh active Pending
- 1998-04-20 CA CA002287538A patent/CA2287538A1/en not_active Abandoned
- 1998-04-20 NZ NZ514872A patent/NZ514872A/en unknown
- 1998-04-20 EA EA199900861A patent/EA199900861A1/ru unknown
- 1998-04-20 NZ NZ500530A patent/NZ500530A/en unknown
- 1998-04-20 KR KR1019997009857A patent/KR20010020259A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ500530A (en) | 2001-12-21 |
JP2001524828A (ja) | 2001-12-04 |
CA2287538A1 (en) | 1998-11-05 |
IL132537A0 (en) | 2001-03-19 |
CN1680442A (zh) | 2005-10-12 |
CN1260835A (zh) | 2000-07-19 |
WO1998049300A3 (en) | 1999-03-11 |
NZ514872A (en) | 2005-01-28 |
KR20010020259A (ko) | 2001-03-15 |
AU7250298A (en) | 1998-11-24 |
EP0977854A2 (en) | 2000-02-09 |
WO1998049300A2 (en) | 1998-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA199900861A1 (ru) | Усеченные белки, родственные фактору роста эндотелия сосудов | |
RU95115239A (ru) | Аналог эритропоэтина | |
AU1922101A (en) | Human fgf-21 gene and gene expression products | |
EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
DE68903846T2 (de) | Neue galenische form von fenofibrat. | |
ATE309360T1 (de) | Vaskularer endothelialer wachstumsfaktor 2 | |
FI885543A0 (fi) | Dna-segment, polypeptider och anti-kroppar anslutande till human vaevnadsfaktor. | |
DE3788961T2 (de) | Verfahren zur herstellung von polysubstituierten diethylentriaminpentaessigsäuren. | |
DE502004011252D1 (de) | Verwendung des erythropoietins zur regeneration von lebergewebe | |
DE69433013D1 (de) | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten | |
ATE347910T1 (de) | Zusammensetzungen zur behandlung von ischamischem gewebe | |
DK0473724T3 (da) | Et humant cytokin, interleukin-9 | |
RU92016244A (ru) | Производные сахарина-ингибиторы протеолитических ферментов | |
WO2002064157A3 (en) | Localized myocardial injection method for treating ischemic myocardium | |
DE3268915D1 (en) | Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions | |
WO1995028907A3 (en) | Megapoietin: a novel megakaryocyte growth promoting factor | |
RU93005051A (ru) | Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации | |
AU8502198A (en) | Method for treating vascular proliferative diseases with p27 and fusions thereof | |
RU94046426A (ru) | Фармацевтические композиции, способы лечения лейкоза, способ повышения уровней стволовых клеток, антагонист с - kit - лиганда, антисмысловая нуклеиновая кислота, способ лечения меланомы, способ усиления трансфекции, способ переноса гена, способ увеличения уровней периферической крови, способ повышения уровней тромбоцитов, способы модификации биологической функции, способ лечения анемии, способ улучшения приживления костного мозга, способ ускорения восстановления костного мозга, способ лечения лейкопении | |
ATE363293T1 (de) | Injektion von autologem knochenmark in den herzmuskel | |
EP0061141A3 (en) | Chemokinesins and chemotaxins of leukocytes and inflamed tissues: natural mediator proteins for reversible promotion of random and directional locomotion (chemokinesis and chemotaxis) for accumulation of specific leukocyte types, process of their biotechnical preparation and pharmaceutical compositions | |
FR2644066B1 (fr) | Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques | |
EA200200533A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo | |
FI103577B1 (fi) | Menetelmä, DNA ja mikro-organismi trombolyyttisen aineen valmistamiseksi | |
EA199901002A1 (ru) | Методы и составы для лечения сердечной недостаточности и вентикулярной коррекции путем доставки in vivo ангиогенных трансгенов |